More Than 15 Years Experience: Takeda Marks one Billion Treatment Courses of Gastric Ulcer Drug Pantoprazole

More Than 15 Years Experience: Takeda Marks one Billion Treatment Courses of Gastric Ulcer Drug Pantoprazole PR Newswire ZURICH, October 22, 2012 ZURICH, October 22, 2012 /PRNewswire/ -- Takeda Pharmaceuticals International GmbH ("Takeda") today announced that over one billion treatment courses of its [1]gastrointestinal product pantoprazole have been administered around the world. Initially launched in 1994 in Germany, pantoprazole, a proton pump inhibitor (PPI) used to treat acid related diseases, is available in more than 90 countries as a prescription treatment and over-the-counter product. Throughout the 17 years of experience with pantoprazole, ongoing clinical trials have continued to deepen medical experience and understanding. Most recently, in April 2012 the first clinical trial evaluating tolerability, safety and efficacy of a PPI in patients with chronic peptic complaints over fifteen years of drug administration was published in the [2]Journal Alimentary Pharmacology and Therapeutics by Prof. Brunner and co-workers from the University Medical School Hannover. The results of the analysis (n=142) demonstrated that daily pantoprazole maintenance therapy for up to 15 years for severe acid-peptic disease was effective and well tolerated. The results of the analysis (n=142) reinforced that daily Pantoprazole maintenance therapy for up to 15 years for severe acid-peptic disease is effective and well tolerated. No safety concerns were identified.